In August, we wrote that FDA's Pharmacy Compounding Advisory Committee ("PCAC") recommendations could mark an inflection point for peptide compounding. PCAC had recommended six peptides for inclusion on the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Although those recommendations did not change the law, we identified enforcement discretion with compliance obligations as a potential path to access before completing formal rulemaking.
That path is now here.
Today, the Department of Health and Human Services ("HHS") released an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The policy covers the same six peptides PCAC recommended in July and allows qualifying 503A compounding to proceed while FDA continues the rulemaking process for the Section 503A Bulks List. HHS states that future rulemakings may propose adding some or all of the substances to the permanent list.
The development is significant in its own right, but the details steal the show. HHS did not simply announce that it would temporarily refrain from enforcement – it created a detailed interim framework governing which peptides may be compounded, the forms and routes permitted, where APIs may come from, how they must be characterized and tested, what compounders must report, and other conditions that must be met for the enforcement policy to apply. HHS also expressly reserves the ability to revisit that discretion if safety signals or product quality issues arise.
For businesses currently participating in or evaluating the peptide market, the question is now whether a particular business, product, supply chain, and prescribing model fit within the pathway HHS has created.
A Regulated Alternative to the Gray Market
The rationale HHS gives for the policy is notable. HHS states that the limited enforcement discretion policy is designed to discourage the widespread use of certain Research Use Only peptides supplied by foreign manufacturers that pose safety risks to U.S. patients. By permitting limited compounding subject to safeguards, HHS intends to provide a more controlled alternative. The Agency describes the policy as advancing patient choice and freedom while protecting patient safety.
That rationale is consistent with HHS Secretary Robert F. Kennedy Jr.'s comments last week that the Administration wanted a regulated marketplace for peptides. It also puts the policy in a different posture from simple deregulation. HHS is responding to existing demand by attempting to move access into a regulated channel with defined conditions.
The conditions are substantial. Among other requirements, the peptide must appear on the new 503A Interim Access Listand conform to the identity and route limitations specified by HHS. The bulk drug substance must come from a Section 510-registered facility and be supported by a certificate of analysis meeting detailed testing criteria. The original manufacturer must be FDA-registered and CGMP-compliant. Compounders must report serious adverse events and product quality issues and provide specified product information to FDA and relevant states. Products must contain only one API appearing on the Interim Access List and carry specified labeling. Patient-specific prescription and other applicable Section 503A requirements continue to apply.
This is permissive compounding, but it is not unrestricted compounding.
The Six Peptides Do Not All Receive the Same Treatment
The policy also underscores why simply saying that a peptide is "on the list" is not enough. HHS specifies the permitted substance and routes for each peptide. BPC-157 acetate receives enforcement discretion for subcutaneous, intramuscular, oral, and topical forms. TB-500 acetate is limited to subcutaneous or intramuscular injectable dosage forms. Epitalon acetate is permitted in subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses. Semax free base is limited to intranasal use. KPV acetate is permitted for topical and oral dosage forms, while MOTS-c acetate is permitted for subcutaneous or intramuscular injectable dosage forms.
Oral products receive additional scrutiny. Where a peptide is compounded in an oral dosage form, the policy expects the compounder to maintain documentation confirming that the specific formulation achieves adequate oral bioavailability in humans.
These distinctions matter immediately for product planning, diligence, contracting, and valuation. The actual API form, formulation, route, supplier, testing, prescription, and dispensing model matter.
HHS Is Managing Uncertainty Rather Than Waiting for It to Disappear
Appendix B provides another important insight into the policy. For each peptide, HHS explains why it concluded that interim enforcement discretion is appropriate notwithstanding CDER's earlier recommendations against listing the substances. The explanations differ by peptide, but recurring considerations include additional characterization data from FDA-registered facilities, greater documentation of historical use, the nature of the safety concerns previously identified, and safeguards incorporated into the new policy.
For BPC-157, for example, HHS identifies additional evidence concerning historical use and human studies, lot-specific characterization addressing information CDER previously found lacking, and the protections created by lot-level testing, single-API products, and MedWatch reporting. For several other substances, HHS similarly points to a changed characterization record and distinguishes mechanistic or inferential concerns from observed safety signals.
The result is an interesting regulatory approach. HHS has not concluded that these compounded products are FDA-approved, nor does the policy mean FDA has completed the statutory Bulks List process. Instead, HHS is permitting access under conditions designed to address identified uncertainty while the formal process continues.
Importantly, the concept of an interim policy while FDA completes the 503A Bulks List is not itself new. FDA already maintains an interim policy addressing compounding from nominated bulk drug substances while the agency develops the list. What is notable here is the specificity of the peptide framework, including a defined Interim Access List, substance-specific conditions, extensive API characterization requirements, active safety surveillance, and express authority to revisit the policy as new information develops.
The Interim Period May Generate Evidence for What Comes Next
The reporting requirements deserve particular attention. Compounders must report serious adverse events associated with use of the compounded drug in humans, regardless of whether the event is considered drug related, as well as specified product quality problems. HHS requires reporting through FDA's MedWatch program and to relevant states. The policy explains that these requirements give FDA and states an opportunity to act on emerging risks.
The policy also requires reporting of information concerning the active ingredient and strength, original API manufacturer, manufacturing facility identifier, dosage form, and route of administration. Products generally must contain only a single API from Appendix A, which HHS says will make it easier to attribute adverse events or clinical outcomes to a particular substance and improve safety surveillance and signal detection.
At the same time, HHS expressly reserves the ability to revisit the policy, in whole or in part, if a safety signal or product quality problem arises.
Taken together, those provisions create more than a temporary access mechanism. The interim period can also generate information about product quality and safety while FDA considers the ultimate regulatory treatment of these substances. That may make what happens during the interim period relevant to what comes after it.
For industry, there is a corresponding implication: execution matters. Problems associated with quality, sourcing, or safety will not necessarily remain isolated compliance events when HHS has expressly tied continuing enforcement discretion to emerging safety and product quality information.
Five Questions Businesses Should Be Asking Now
1. Can We Meet the Policy's API, Testing, and Product Quality Requirements?
The policy establishes detailed expectations for peptide identity and characterization, certificates of analysis, manufacturing sources, purity, potency, and contaminants. Appendix B goes further, identifying analytical methods and quality attributes relevant to peptide characterization.
Compounders should compare current API specifications, supplier documentation, testing, COAs, and finished product controls directly against the new requirements. Suppliers should be conducting the same exercise from the other side of the transaction.
2. Can We Build the Safety and Product Quality Reporting Infrastructure the Policy Requires?
The reporting obligation is operational, not theoretical. HHS requires reporting of serious adverse events even when they are not considered drug related, as well as specified product quality issues. The required information must be capable of moving between patients, prescribers, pharmacies, quality functions, FDA, and applicable states.
Companies should determine where safety information enters their systems, who evaluates it, how it is connected to a particular product and lot, and how reportable events are escalated.
3. Does Our Supply Chain Meet the Manufacturer and Traceability Requirements?
The policy reaches upstream to the original API manufacturer. It addresses FDA registration, CGMP compliance, facility identification, COAs, and vendor validation where repackers, relabelers, or resellers are involved.
That makes API provenance a central issue for compounders and an important diligence question for telehealth platforms, investors, lenders, acquirers, and other counterparties.
4. Does Our Actual Product and Patient Care Model Fit the Policy?
Companies should test their actual model against the policy rather than treating inclusion of the peptide itself as sufficient.
Which API form is being used? Is the route permitted? Does the product contain only one listed API? If it is oral, is there adequate human bioavailability documentation? How is the patient-specific prescription generated and documented? Do labeling and any co-packaged devices satisfy the applicable conditions?
For telehealth and integrated pharmacy models, the relevant analysis therefore extends from API sourcing through the patient encounter, prescription, compounding, dispensing, and safety follow-up.
5. How Should We Build a Business Strategy Around an Interim Policy That Can Change?
The policy creates an immediate opportunity, but its interim character matters. HHS may revisit it if safety or product quality issues arise, and future rulemaking may propose adding some or all of the six peptides to the permanent 503A Bulks List.
Companies should identify which assumptions concerning the policy are embedded in forecasts, contracts, investments, acquisitions, financing arrangements, supplier commitments, and expansion plans. Investors and lenders should test the same assumptions during diligence.
The relevant strategic question is not simply whether the policy creates an opportunity today. It is whether the business is structured to capture that opportunity while remaining resilient as the final regulatory framework develops.
What Comes Next
The July PCAC Bulks List meeting now looks different than it did three months ago. The six favorable recommendations did not themselves change the law. They did, however, identify the same six peptides that HHS has now placed on its Interim Access List. The intervening period brought a proposed Interim Access Policy, White House review, public support from the HHS Secretary for a regulated peptide marketplace, congressional pressure for enforcement discretion, and now a detailed HHS policy governing interim access.
The next question is no longer simply whether FDA will accept or reject PCAC's recommendations. FDA still has to work through the rulemaking process, and HHS makes clear that future rulemakings may propose adding some or all of the six peptides to the 503A Bulks List.
In the meantime, however, businesses have an actual framework against which to evaluate their operations.
For compounders, telehealth platforms, prescribers, API suppliers, investors, lenders, acquirers, and strategic partners, the opportunity created by this policy will depend in significant part on the ability to operate within its conditions.
How Vedder Can Help
Vedder's FDA Regulatory Strategy & Compliance Practice advises 503A and 503B pharmacies, telehealth platforms, prescribers, suppliers, investors, lenders, acquirers, and other market participants on compounding strategy, quality and compliance systems, prescribing models, enforcement exposure, and transaction risk. We help clients evaluate how new FDA and HHS policies apply to their specific operations, identify regulatory and commercial opportunities and risks, and develop practical strategies for operating in evolving regulatory environments.
For companies participating in or evaluating the peptide market, that analysis can include assessing current operations against the new HHS enforcement discretion framework, evaluating product and supply chain eligibility, reviewing prescribing and reporting systems, and incorporating the interim policy into business planning and regulatory diligence.
